Terlipressin for septic shock patients: a meta-analysis of randomized controlled study.

Abstract

BACKGROUND:

Catecholamines are commonly used in septic shock but face limitations of their hypo-responsiveness and adverse events due to high dose. Terlipressin is a synthetic vasopressin analog with greater selectivity for the V1-receptor. A meta-analysis was conducted to evaluate the efficacy and safety of terlipressin in septic shock.

METHODS:

We searched for relevant studies in PubMed, Embase, and the Cochrane database from inception up to July 15, 2018. Randomized controlled trials (RCTs) were included if they reported data on any of the predefined outcomes in patients with septic shock and managed with terlipressin or any catecholamines. Results were expressed as risk ratio (RR) or mean difference (MD) with accompanying 95% confidence interval (CI). Heterogeneity, subgroup analysis, sensitivity analysis, and publication bias were explored.

RESULTS:

Ten studies with 928 patients were included. Despite the shorter duration of mechanical ventilation, use of terlipressin did not reduce the risk of mortality (RR = 0.94; 95% CI, 0.85 to 1.05; I 2 = 0%; P = 0.28) when compared with control. This finding was confirmed by further subgroup and sensitivity analyses. In addition, lactate clearance, length of stay in ICU or hospital, total adverse events, digital ischemia, and arrhythmia were also similar between groups, while terlipressin was associated with shorter duration of mechanical ventilation and less norepinephrine requirements.

CONCLUSIONS:

Current results suggest terlipressin did not show added survival benefit in septic shock therapy when compared with catecholamines.

• Authors: Yibing Zhu, Huibin Huang, Xiuming Xi, Bin Du
• Journal: Journal of intensive care (J Intensive Care) Vol. 7 Pg. 16 ( 2019) ISSN: 2052-0492 [Print] England
• PMID: 30923620 (Publication Type: Journal Article)